Yumanity Therapeutics to Present at the BTIG Virtual Biotechnology Conference
Yumanity Therapeutics (NASDAQ: YMTX), a biopharmaceutical company focusing on neurodegenerative diseases, announced participation in a fireside chat at the BTIG Virtual Biotechnology Conference on August 10, 2021, at 1:00 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Yumanity Therapeutics (NASDAQ: YMTX), a biopharmaceutical company focusing on neurodegenerative diseases, announced participation in a fireside chat at the BTIG Virtual Biotechnology Conference on August 10, 2021, at 1:00 p.m. ET. This event is exclusive to BTIG clients. Yumanity is advancing innovative therapies, with its lead candidate, YTX-7739, in Phase 1 for Parkinson’s disease. The company aims to overcome misfolded protein toxicity through its drug discovery platform, targeting conditions such as Lewy body dementia, ALS, FTLD, and Alzheimer’s.
Details
News Market Reaction – YMTX
The recorded move for YMTX in the trading session of this news was +0.57%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Company management will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, August 10, 2021, at 1:00 p.m. ET.
BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative.
About Yumanity Therapeutics
Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company’s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson’s disease. Yumanity’s drug discovery platform enables the Company to rapidly screen for potential disease-modifying therapies by overcoming the toxicity of misfolded proteins associated with neurogenerative diseases. Yumanity’s pipeline consists of additional programs focused on Lewy body dementia, multi-system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), frontotemporal lobar dementia (FTLD), and Alzheimer’s disease. For more information, please visit www.yumanity.com.
Investors:
Burns McClellan, Inc.
Lee Roth
lroth@burnsmc.com
(212) 213-0006
Media:
Burns McClellan, Inc.
Robert Flamm, Ph.D. / Harrison Wong
rflamm@burnsmc.com / hwong@burnsmc.com
(212) 213-0006 ext. 364 / 316
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.